Advertisement

Perspectives on Dopamine as a Regulator of Brain Function

  • A. Carlsson

Abstract

The profound effect of cerebral dopamine on mental and motor functions is well documented. In 1957 Courvoisier demonstrated the rather extreme immobility induced by chlorpromazine, a number of congeners of this agent, and reserpine. This condition is generally referred to as catalepsy. The animal can be placed and remains in the most awkward positions. The underlying mechanism was not understood at that time, but the same year it was discovered that this condition, when induced by reserpine, could be reversed by the catecholamine precursor dopa. This led to the discovery of dopamine as a normal brain constituent, and the reversal of catalepsy could be related to the accumulation of dopamine in the brain. Five years later evidence was presented suggesting that the central actions induced by chlorpromazine and other major neuroleptics are due to blockade of dopamine receptors. Since then the literature on dopamine has grown considerably, up to about 1000 new publications every year, and it is fair to say that we have a reasonably good understanding of the role of this neurotransmitter for various brain functions, although our knowledge is incomplete in many respects (for review, see Carlsson 1987).

Keywords

Dopamine Receptor Reticular Formation Ventral Striatum Dorsal Striatum Mesencephalic Reticular Formation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arieti SA (1966) Schizophrenic cognition. In: Hoch PH, Zubin J (eds) Psychopathology of schizophrenia. Grune and Stratton, New York, pp 37–48Google Scholar
  2. Berggren U (1985) Effect of chronic lithium treatment on brain monoamine metabolism and amphetamine-induced locomotor stimulation in rats. J Neural Transm 64: 239–250PubMedCrossRefGoogle Scholar
  3. Bjòrklund A, Lindvall O (1986) Catecholaminergic brain stem regulatory systems. In: Field J (ed) Handbook of physiology. The nervous system IV. American Physiological Society, Washington, DC, pp 155–235Google Scholar
  4. Brown RM, Crane AM, Goldman PS (1979) Regional distribution of monoamines in the cerebral cortex and subcortical structures of the rhesus monkey: concentrations and in vivo synthesis rates. Brain Res 168: 133–150PubMedCrossRefGoogle Scholar
  5. Carlsson A (1987) Perspectives on the discovery of central monoaminergic neurotransmission. Annu Rev Neurosci 10: 19–40PubMedCrossRefGoogle Scholar
  6. Farde L, Pauli S, Hall H, Stone Elander S, Eriksson L, Halldin C, Hógberg T, Nilsson L, Sjogren I (1988) Stereoselective binding of llC-raclopride - a search for extrastriatal central D2-dopamine receptors by PET. Psychopharmacology (Berlin) 94: 471–478CrossRefGoogle Scholar
  7. Goldman-Rakic PS, Selemon LD (1986) Topography of corticostriatal projections in nonhuman primates and implications for functional panellation of the neostriatum. In: Jones EG, Peters A (eds) Cerebral cortex, vol 5. Plenum, New York, pp 447–466Google Scholar
  8. Heimer L, Alheid GF, Zaborszky L (1985) Basal ganglia. In: Paxinos G (ed) The rat nervous system, vol 1. Forebrain and midbrain. Academic, New York, pp 37–86Google Scholar
  9. Hornykiewicz O (1980) Biochemical abnormalities in some extrastriatal neuronal systems in Parkinson’s disease. In: Rinne UK, Klingler M, Stamm G (eds) Parkinson’s disease. Current progress, problems and management. Elsevier, Amsterdam, pp 109–120Google Scholar
  10. Iversen SD (1977) Brain dopamine systems and behavior. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology, vol 8. Plenum, New York, pp 333–384CrossRefGoogle Scholar
  11. Klein DF (1988) Rheostat and cybernetic issues. Comments on “The current status of the dopamine hypothesis of schizophrenia”. Neuropsychopharmacology 1: 187–188PubMedCrossRefGoogle Scholar
  12. Klein DF, Gittelman R, Quitkin F, Rifkin A (1980) Diagnosis and drug treatment of psychiatric disorders: adults and children. In: Klein DF, Gittelman R, Quitkin F, Rifkin A (eds) Diagnosis and drug treatment of psychiatric disorders: adults and children. Williams and Wilkins, Baltimore, pp 810–815Google Scholar
  13. Lehmann H (1966) Pharmacotherapy of schizophrenia. In: Hoch PH, Zubin J (eds) Psycho-pathology of schizophrenia. Grune and Stratton, New York, pp 120–133Google Scholar
  14. Manallack DT, Beart PM, Gundlach AL (1986) Psychotomimetic sigma-opiates and PCP. Trends Pharmacol Sci 7: 448–451CrossRefGoogle Scholar
  15. Mattsson B (1974) Huntington’s chorea in Sweden. II. Social and clinical data. Acta Psychiat Scand [Suppl] 255: 221–235CrossRefGoogle Scholar
  16. McGhie A, Chapman J (1961) Disorders of attention and perception in early schizophrenia. Br J Med Psychol 34: 103–110PubMedCrossRefGoogle Scholar
  17. Ottersen OP, Storm-Mathisen J (1984) Neurons containing or accumulating transmitter amino acids. In: Bjorklund A, Hókfelt T, Kuhar MJ (eds) Handbook of chemical neuroanatomy, vol 3. Elsevier, Amsterdam, pp 141–246Google Scholar
  18. Reynolds GP (1983) Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature 305: 527–529PubMedCrossRefGoogle Scholar
  19. Roland PE (1987) Changes in brain blood flow and oxidative metabolism during mental activity. News in Physiol Sci 2: 120–124Google Scholar
  20. Selemon LD, Goldman-Rakic PS (1985) Longitudinal topography and interdigitation of corticostriatal projections in the rhesus monkey. J Neurosci 5: 776–794PubMedGoogle Scholar
  21. Svensson K, Hjorth S, Clark D, Carlsson A, Wikstrom H, Andersson B, Sanchez D, Johansson AM, Arvidsson L-E, Hacksell U, Nilsson JLG (1986a) (+)-UH 232 and (+)- UH242: novel stereoselective DA receptor antagonists with preferential action on autoreceptors. J Neural Transm 65: 1–27Google Scholar
  22. Svensson K, Johansson AM, Magnusson T, Carlsson A (1986b) (+)-AJ 76 and (+)-UH 232: Central stimulants acting as preferential dopamine autoreceptor antagonists. Naunyn- Schmiedeberg’s Arch Pharmacol 334: 234–245Google Scholar
  23. Venables PH (1964) Input dysfunction in schizophrenia. In: Maher B (ed) Progress in experimental personality research. Academic, New York, pp 1–41Google Scholar
  24. Willner P (1985) Depression. A psychobiological synthesis. In: Willner P (ed) Depression. A psychobiological synthesis. Wiley, New York, pp 170–172Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • A. Carlsson
    • 1
  1. 1.Department of PharmacologyUniversity of GothenburgGothenburgSweden

Personalised recommendations